Treatment and evaluation
toxicity, toxicities
Everolimus 10 mg daily continuously was combined with temozolomide 150 mg/mFor haematological toxicities, both drugs were held at the occurrence of Grade ≥3 toxicity and re-administered at the subordinate dose level (everolimus 5 mg daily continuously and temozolomide 100 mg/mCT evaluation was performed at baseline (before 4 weeks of treatment initiation), after 6 weeks of treatment, and thereafter every 8 weeks, and the response was evaluated according to RECIST v. 1.1. [18F]FDG-PET/CT was performed at baseline and after 6 weeks of treatment with response evaluation according to PET Response Criteria in Solid Tumours version 1.0 (PERCIST v. 1.0) [